Literature DB >> 20484976

Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling.

Brian Tomkowicz1, Katherine Rybinski, Denise Sebeck, Philip Sass, Nicolas C Nicolaides, Luigi Grasso, Yuhong Zhou.   

Abstract

Recent reports have described several cellular phenotypes that appear to be mediated by Endosialin/TEM-1/CD248 (TEM-1), including tubule formation on matrigel, migration and proliferation. It has been shown that siRNA knock-down of TEM-1 in primary human fibroblasts resulted in reduced proliferation. However, the downstream signaling events that mediate TEM-1 function(s) currently remain unknown. In this study, we demonstrate that TEM-1 mediates proliferation of primary human pericytes through a PDGF receptor signaling pathway. Normal pericytes expressing high levels of TEM-1 were able to proliferate, respond to PDGF-BB stimulation by phosphorylating both the PDGF receptor and the MAP kinase ERK-1/2, and induce the expression of the immediate early transcription factor c-Fos. However, when TEM-1 expression was knocked-down, PDGF-BB-induced proliferation, ERK-1/2 phosphorylation, and c-Fos expression were significantly impaired. Thus, our results provide evidence for a TEM-1-dependent signal pathway that controls proliferation of human pericytes and suggest targeting this pathway for future strategies aimed at mitigating tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484976     DOI: 10.4161/cbt.9.11.11731

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  39 in total

1.  A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.

Authors:  Luis A Diaz; Christina M Coughlin; Susan C Weil; Jean Fishel; Mrinal M Gounder; Susan Lawrence; Nilofer Azad; Daniel J O'Shannessy; Luigi Grasso; Jason Wustner; Wolfgang Ebel; Richard D Carvajal
Journal:  Clin Cancer Res       Date:  2014-11-14       Impact factor: 12.531

Review 2.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

3.  Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).

Authors:  Robin E Norris; Elizabeth Fox; Joel M Reid; Andrew Ralya; Xiaowei W Liu; Charles Minard; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2018-01-02       Impact factor: 3.167

4.  Isolation of CD248-expressing stromal vascular fraction for targeted improvement of wound healing.

Authors:  Elizabeth Brett; Elizabeth R Zielins; Monica Chin; Michael Januszyk; Charles P Blackshear; Michael Findlay; Arash Momeni; Geoffrey C Gurtner; Michael T Longaker; Derrick C Wan
Journal:  Wound Repair Regen       Date:  2017-05-18       Impact factor: 3.617

5.  Pericyte regulation of vascular remodeling through the CXC receptor 3.

Authors:  Richard J Bodnar; Margaret E Rodgers; William C W Chen; Alan Wells
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-17       Impact factor: 8.311

6.  The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice.

Authors:  Amy J Naylor; Eman Azzam; Stuart Smith; Adam Croft; Callum Poyser; Jeremy S Duffield; David L Huso; Steffen Gay; Caroline Ospelt; Mark S Cooper; Clare Isacke; Simon R Goodyear; Michael J Rogers; Christopher D Buckley
Journal:  Arthritis Rheum       Date:  2012-10

7.  CD248 expression on mesenchymal stromal cells is required for post-natal and infection-dependent thymus remodelling and regeneration.

Authors:  Siân Lax; Ewan A Ross; Andrea White; Jennifer L Marshall; William E Jenkinson; Clare M Isacke; David L Huso; Adam F Cunningham; Graham Anderson; Christopher D Buckley
Journal:  FEBS Open Bio       Date:  2012-07-20       Impact factor: 2.693

8.  CD248 facilitates tumor growth via its cytoplasmic domain.

Authors:  Margarida Maia; Astrid DeVriese; Tom Janssens; Michaël Moons; Rik J Lories; Jan Tavernier; Edward M Conway
Journal:  BMC Cancer       Date:  2011-05-08       Impact factor: 4.430

Review 9.  Characteristics of human Ewing/PNET sarcoma models.

Authors:  Beverly A Teicher; Rebecca G Bagley; Cecile Rouleau; Ariel Kruger; Yi Ren; Leslie Kurtzberg
Journal:  Ann Saudi Med       Date:  2011 Mar-Apr       Impact factor: 1.526

10.  A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

Authors:  Sandra P D'Angelo; Omid A Hamid; Ahmad Tarhini; Dirk Schadendorf; Bartosz Chmielowski; Frances A Collichio; Anna C Pavlick; Karl D Lewis; Susan C Weil; John Heyburn; Charles Schweizer; Daniel J O'Shannessy; Richard D Carvajal
Journal:  Invest New Drugs       Date:  2017-11-11       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.